Afuco™ Anti-IAV HA ADCC Therapeutic Antibody (Navivumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Influenza A virus HA. Navivumab is a human monoclonal antibody that can be potentially used in the treatment of Influenza. It inhibits the entry of influenza virus into host cells by blocking HA-mediated membrane fusion.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-438CQ |
| Pricing | Inquiry |
| Host | Human |
| Target | IAV HA |
| Species Reactivity | Influenza A virus |
| Type | ADCC enhanced antibody |
| Applications | ELISA, IHC, FC, IP, IF, BL |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |